MA45288A - Nouvelle utilisation médicale de probiotiques - Google Patents

Nouvelle utilisation médicale de probiotiques

Info

Publication number
MA45288A
MA45288A MA045288A MA45288A MA45288A MA 45288 A MA45288 A MA 45288A MA 045288 A MA045288 A MA 045288A MA 45288 A MA45288 A MA 45288A MA 45288 A MA45288 A MA 45288A
Authority
MA
Morocco
Prior art keywords
probiotics
medical use
new medical
new
medical
Prior art date
Application number
MA045288A
Other languages
English (en)
Inventor
Andrea Biffi
Walter Fiore
Ruggero Rossi
Original Assignee
Sofar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sofar Spa filed Critical Sofar Spa
Publication of MA45288A publication Critical patent/MA45288A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA045288A 2016-06-08 2017-06-08 Nouvelle utilisation médicale de probiotiques MA45288A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUA2016A004188A ITUA20164188A1 (it) 2016-06-08 2016-06-08 Nuovo uso medico di probiotici

Publications (1)

Publication Number Publication Date
MA45288A true MA45288A (fr) 2019-04-17

Family

ID=57133304

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045288A MA45288A (fr) 2016-06-08 2017-06-08 Nouvelle utilisation médicale de probiotiques

Country Status (11)

Country Link
US (1) US11752179B2 (fr)
EP (2) EP4272815A3 (fr)
CN (1) CN109310719A (fr)
AU (1) AU2017279037A1 (fr)
BR (1) BR112018074795A2 (fr)
CL (1) CL2018003487A1 (fr)
CO (1) CO2018010954A2 (fr)
IT (1) ITUA20164188A1 (fr)
MA (1) MA45288A (fr)
MX (1) MX2018012781A (fr)
WO (1) WO2017212433A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
WO2019149941A1 (fr) * 2018-02-02 2019-08-08 Postbiotica S.R.L. Composition à base de postbiotiques pour la modulation de l'activation du système immunitaire et la protection des barrières muqueuses
JP7364170B2 (ja) 2018-03-15 2023-10-18 ユニバーシティ オブ サザン カリフォルニア 水のみの絶食ではない断食模倣食（ｆｍｄ）は炎症及びｉｂｄ病状からの回復を促進する
CN112236154B (zh) * 2018-05-31 2024-10-18 深圳华大生命科学研究院 一种组合物及其应用
CN110129221B (zh) * 2019-05-06 2022-05-17 福建晋江国食文化传媒有限公司 乳酸菌hwn19菌株及其应用
CN110184214B (zh) * 2019-05-21 2022-07-01 黑龙江大学 一种开菲尔乳杆菌及其菌制剂
CN110144311B (zh) * 2019-05-21 2022-07-01 黑龙江大学 一种开菲尔乳杆菌及其菌制剂
JP6739602B1 (ja) * 2019-07-24 2020-08-12 雪印メグミルク株式会社 記憶・学習能維持および／または向上用組成物及び組成物を含む食品、医薬品、飼料
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
AU2020379517B2 (en) * 2019-11-08 2024-07-18 Biogaia Ab Serotonin producing bacteria
US20210275612A1 (en) * 2020-03-09 2021-09-09 Glac Biotech Co., Ltd. Method for alleviating inflammation-related disorder
JP7663322B2 (ja) * 2020-04-08 2025-04-16 雪印メグミルク株式会社 ビフィズス菌増殖促進剤
US12478651B2 (en) 2020-04-08 2025-11-25 Megmilk Snow Brand Co., Ltd. Composition for improving gut microbiota
JP2022052715A (ja) * 2020-09-23 2022-04-04 雪印メグミルク株式会社 腸内細菌叢改善用組成物
CN112956653A (zh) * 2021-04-09 2021-06-15 吉林大学 一种蓝莓鹿肉发酵香肠及其制备方法
CN112971053A (zh) * 2021-04-20 2021-06-18 吉林大学 一种大豆低聚肽糖果香肠及其制备方法
CN115702908A (zh) * 2021-08-05 2023-02-17 香港中文大学 用于治疗和预防结肠直肠癌的益生菌组合物
CN114196599A (zh) * 2022-01-06 2022-03-18 北京浩鼎瑞微生态科技研究院有限公司 一种用于肠道菌群调和的微生物组合物及其制备方法
IT202200010244A1 (it) * 2022-05-17 2023-11-17 Alfasigma Spa Lacticaseibacillus paracasei DG® CNCM I-1572 DSM 34154 per uso in un metodo di trattamento della disbiosi in pazienti affetti da IBS
CA3268072A1 (fr) 2022-09-30 2024-04-04 Evonik Operations Gmbh Souches probiotiques pour le traitement du syndrome du côlon irritable et de l'intolérance aux fodmap
US12268717B1 (en) 2024-03-01 2025-04-08 Malireddy S. Reddy Enhanced microbial therapeutic agents
CN117866857B (zh) * 2024-03-13 2024-05-28 中国农业大学 一种缓解肠道炎症的富硒棒状乳杆菌h8及其制备方法与应用

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517363A (ja) 1991-07-11 1993-01-26 Yakult Honsha Co Ltd 抗炎症剤及びそれを含有する化粧料
US5716615A (en) * 1992-02-10 1998-02-10 Renata Maria Anna Cavaliere Vesely Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
CN1066926C (zh) 1996-04-08 2001-06-13 钟春燕 将椰子水发酵制作的食用纤维及其生产方法
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CZ9900769A3 (cs) 1999-03-04 2000-10-11 Petr Ing. Drsc. Hušek Použití špičky s filtrem k vytvoření sloupce sorbentu s definovaným objemem v prostoru pod filtrem
US20020090416A1 (en) 1999-03-09 2002-07-11 Philip Connolly Method of enhancing absorption and utilization of protein
IT1307850B1 (it) 1999-03-15 2001-11-19 Italmed Di Galli Giovanna E Pa Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio
EP1145643A1 (fr) 2000-04-10 2001-10-17 Phillip Connolly Concentré de lactoprotéines amelioré
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
RU2182008C1 (ru) 2000-10-20 2002-05-10 Самойленко Игорь Иннокентьевич Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
FI20020078A7 (fi) 2002-01-15 2003-07-16 Danisco Immuunijärjestelmän stimulointi polydextroosilla
US6881419B2 (en) 2002-04-09 2005-04-19 William E. Lovett Vitamin formulation for enhancing bone strength
CN1627948A (zh) 2002-04-24 2005-06-15 麦迪卡博公司 治疗炎症性肠病的组合物和试剂盒
EP1530642B1 (fr) 2002-08-06 2009-12-30 Danisco A/S Utilisation de lactobacillus pour produire des exopolysaccharides dans des produits alimentaires ou pharmaceutiques
AU2002951270A0 (en) 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
WO2005001109A2 (fr) 2003-05-06 2005-01-06 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Procedes et compositions permettant de detecter des microbes dans des echantillons fecaux
US20100112088A1 (en) 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
WO2005083122A2 (fr) 2004-02-27 2005-09-09 Stichting Laboratorium Voor Infectieziekten Methode de detection de micro-organisme dans un echantillon fecal
US7510734B2 (en) 2004-03-04 2009-03-31 E-L Management Corporation Skin treatment method with Lactobacillus extract
US20090197249A1 (en) 2004-11-01 2009-08-06 George Mason University Compositions and methods for diagnosing colon disorders
CA2601427C (fr) 2005-04-06 2013-06-11 Novartis Ag Methode et composition pouvant ameliorer a des fins nutritionnelles la regulation de la glycemie et l'action de l'insuline
FI20051319L (fi) 2005-12-22 2007-06-23 Cyflo Oy Menetelmä eläimen ja/tai ihmisen ravitsemuksen ja hyvinvoinnin ja eläinten tuottavuuden seuraamiseksi ja kehittämiseksi
CN1840206A (zh) 2006-01-19 2006-10-04 上海交通大学 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法
JP4590573B2 (ja) 2006-02-21 2010-12-01 国立大学法人富山大学 感染症起因菌の迅速同定方法
JP5289936B2 (ja) 2006-02-24 2013-09-11 キユーピー株式会社 新規な低分子ヒアルロン酸および／またはその塩、ならびにこれを用いた化粧料、医薬組成物および食品組成物
WO2007140621A1 (fr) 2006-06-09 2007-12-13 Nutravital Inc. Compositions probiotiques et leurs utilisations
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
US20080081035A1 (en) 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
CA2673120C (fr) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation Produit alimentaire sec contenant un probiotique vivant
EP1972208A1 (fr) 2007-03-16 2008-09-24 Kirin Holdings Kabushiki Kaisha Composition pour améliorer la flore microbienne intestinale
BRPI0809454A2 (pt) 2007-03-27 2014-09-09 Procter & Gamble Métodos e kits para a administração de probióticos
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EP2173196B1 (fr) 2007-07-06 2011-02-16 N.V. Nutricia Utilisation de probiotiques et de fibres pour la diarrhée
US8193155B2 (en) 2009-02-09 2012-06-05 Elc Management, Llc Method and compositions for treating skin
US20090098088A1 (en) 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
CN101240315A (zh) 2008-02-21 2008-08-13 上海交通大学 检测药物防癌效果的非损伤性分子方法
RU2010143460A (ru) * 2008-05-01 2012-06-10 Дзе Проктер Энд Гэмбл Компани (US) Способы и наборы для терапии восстановительных состояний кишечника
WO2010008272A1 (fr) * 2008-07-15 2010-01-21 N.V. Nutricia Traitement de troubles du transit intestinal
JP2010161944A (ja) 2009-01-13 2010-07-29 Syngen Biotech Co Ltd 新型カゼイ菌の亜種（ｓｇ９６）及びこれを含有する菌抑制組成物及びその用途
PT2403510T (pt) * 2009-03-05 2020-04-02 Probiotical Spa Estirpes bacterianas com uma elevada actividade antiinflamatória
WO2010103132A1 (fr) 2009-03-10 2010-09-16 Hero España, S.A. Isolement, identification et caractérisation de souches ayant une activité probiotique à partir de fèces de nourrissons alimentés exclusivement avec du lait maternel
ES2660008T3 (es) 2009-09-23 2018-03-20 Thomas Julius Borody Terapia para infecciones entéricas crónicas
PH12012500687A1 (en) 2009-11-12 2012-10-29 Nestec Sa Nutritional composition for promoting gut microbiota balance and health
NZ600258A (en) 2009-12-22 2014-01-31 Probi Ab Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
EP2451467B1 (fr) * 2010-01-14 2016-12-21 INSERM - Institut National de la Santé et de la Recherche Médicale Bactérie probiotique recombinante pour la prévention et le traitement de la maladie intestinale inflammatoire et du syndrome d'intestin douloureux
ITUD20100112A1 (it) 2010-06-09 2011-12-10 Farma Derma S R L Preparazione per uso vaginale e rettale e relativo procedimento di produzione
WO2012135499A1 (fr) 2011-03-31 2012-10-04 Ganeden Biotech, Inc. Compositions nutritionnelles probiotiques pour l'activité sportive
WO2012154738A1 (fr) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition et procédé pour améliorer la santé intestinale
PT3366143T (pt) 2011-06-20 2025-01-07 Heinz Co Brands H J Llc Composições e métodos probióticos
GB201219873D0 (en) 2012-11-05 2012-12-19 Multigerm Uk Entpr Ltd Diverticulitis treatment
CN102919922A (zh) 2012-11-08 2013-02-13 黑龙江省轻工科学研究院 一种复合益生菌发酵蓝莓果汁粉的制备方法
AU2014226633A1 (en) 2013-03-05 2015-09-03 Academisch Ziekenhuis Groningen Use of Faecali bacterium prausnitzii HTF-F (DSM 26943) to suppress inflammation.
AU2014286177B2 (en) 2013-07-02 2018-01-18 Austrianova Singapore Pte Ltd. A method of freeze-drying encapsulated cells, freeze-dried encapsulated cells, compositions containing freeze-dried encapsulated cells and uses of such cells and compositions
ITMI20131467A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
ITMI20131473A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale
MA39710A (fr) * 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
AU2015258769A1 (en) 2014-05-12 2016-12-01 Medlab Ip Pty Ltd Probiotic compositions and uses thereof for treatment of obesity-related disorders
EP2990045B1 (fr) 2014-08-26 2016-11-16 Chr. Hansen A/S Bifidobacterium animalis subsp. lactis destiné à être utilisé pour réduire la douleur abdominale chez une femme ménopausée
WO2017195182A1 (fr) 2016-05-13 2017-11-16 Sofar S.P.A. Utilisation de probiotiques pour améliorer l'absorption des protéines
IT201600083376A1 (it) * 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
US11207358B2 (en) 2016-12-16 2021-12-28 Compagnie Gervais Danone Probiotic composition comprising Lactobacillus rhamnosus and Lactobacillus paracasei and methods thereof
WO2019019961A1 (fr) 2017-07-26 2019-01-31 海思科医药集团股份有限公司 Microflore destinée à la prévention et au traitement d'une réaction du tube digestif et/ou de la peau et son utilisation
IT201700101704A1 (it) 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
KR102815561B1 (ko) 2017-12-06 2025-05-29 락2바이오메 에스.알.엘. 프로바이오틱스 조성물 및 그 용도
CN108743851A (zh) 2018-08-09 2018-11-06 深圳市博奥生物科技有限公司 一种复合益生菌粉的制备方法及复合益生菌粉
IT201900016865A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e loro uso come antinfiammatori
IT201900016811A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900016850A1 (it) 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e estratti di bacche e loro uso come antinfiammatori
IT201900016805A1 (it) 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900020422A1 (it) 2019-11-05 2021-05-05 Sofar Spa Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems

Also Published As

Publication number Publication date
CN109310719A (zh) 2019-02-05
CO2018010954A2 (es) 2018-12-14
US11752179B2 (en) 2023-09-12
BR112018074795A2 (pt) 2019-03-12
EP4272815A3 (fr) 2024-01-17
AU2017279037A1 (en) 2018-11-22
ITUA20164188A1 (it) 2017-12-08
EP3468574A1 (fr) 2019-04-17
US20190290706A1 (en) 2019-09-26
EP4272815A2 (fr) 2023-11-08
WO2017212433A1 (fr) 2017-12-14
CL2018003487A1 (es) 2019-01-18
MX2018012781A (es) 2019-01-28

Similar Documents

Publication Publication Date Title
MA45288A (fr) Nouvelle utilisation médicale de probiotiques
LT3728870T (lt) Plokščių rinkinys
HUE046756T2 (hu) Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei
EP3389630A4 (fr) Identification de néogènes, fabrication et utilisation
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
HUE040395T2 (hu) Ápolóeszköz és eljárás
HUE055755T2 (hu) Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
HUE043310T2 (hu) COT modulátorok és eljárások alkalmazásukra
FI20165061L (fi) Aluksen itsenäinen käyttö
EP3338783C0 (fr) Utilisation antibactérienne de salicylanilides halogénés
DK3331876T3 (da) Modulators of ror-gamma
HUE060182T2 (hu) Szomatosztatin modulátorok és azok felhasználása
DK3474802T3 (da) Medicinsk forbinding
HUE051713T2 (hu) Szelenoorganikus vegyületeket tartalmazó készítmények és ezek alkalmazása
EP3719114A4 (fr) Nouvelle microalgue et utilisation associée
DK3569166T3 (da) Indretning til akut behandling af hjertestop
PL3197506T3 (pl) Sposób suszenia kanałów endoskopu
HUE043624T2 (hu) Trifluormetil-alkoholok ROR-gamma-t modulátoraiként
EP3434707A4 (fr) Particules creuses et utilisation de ces particules
HUE048503T2 (hu) Dihidropirimidin-2-on vegyületek és gyógyszerészeti alkalmazásai
HUE050688T2 (hu) P-szubsztituált aszimmetrikus ureák és azok orvosi felhasználása
EP3520789A4 (fr) Nouvelle utilisation de l'amlexanox
EP3383886A4 (fr) Histatines et méthodes d'utilisation de celles-ci
PL3505880T3 (pl) Zbieranie zużytego materiału etykietowego
EP3721889A4 (fr) Utilisation debutyribacter intestini